SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) – Alkahest, Inc., a clinical-stage biotechnology company focused on the discovery and development of transformative therapies to treat age-related diseases and a subsidiary of Grifols , today announced the appointment of Dr. CÃ©sar Cerezo MD, Ph.D., as Chief Medical Officer. He will be responsible for leading and providing strategic direction to the clinical and medical development teams.
“Dr. Cerezo brings to Alkahest a solid and extensive experience both as a practicing physician and researcher, and as a seasoned leader in the pharmaceutical and biotechnology industry. Having played an important role in the advancement of several research programs. clinical development in different therapeutic areas in reputable companies such as Amgen and Pfizer, we are confident that Caesar will provide invaluable leadership and strategic vision to the continued development of Alkahest’s exciting portfolio of clinical candidates for age-related disease â said Karoly Nikolich, Ph.D., Chairman of the Board and CEO of Alkahest. âWe warmly welcome Dr. Cerezo to Alkahest as Chief Medical Officer and look forward to the clinical advancements that his supervision and his strategic sense will bring to our team. â
CÃ©sar Cerezo, Alkahest Medical Director, added, âI am delighted to join this passionate and innovative team during such an exciting time for its clinical pipeline, as the Company initiates and completes additional clinical programs to support its unique approach to disease treatment. Through the development of a promising new therapeutic class focused on targeting the plasma proteome, Alkahest has established itself as a leader in reinventing the way we treat age-related diseases, and I look forward to starting to working with the Alkahest team to drive clinical growth and strategy. “
Prior to joining Alkahest, Dr Cerezo was Vice President and Head of Therapeutics for Global Medical Affairs in General Practice at Amgen, where he led global and US medical organizations in Cardiovascular / Metabolic, Bone, Nephrology, Neuroscience. , inflammation and Amgen biosimilars. divisions, overseeing strategy and medical plan execution for over 20 online and pipeline programs. Prior to this role, Dr Cerezo held a number of leadership roles, including US and Global Medical Officer for the Repatha program and other cardio-metabolic portfolio programs at different stages of the development cycle. Prior to joining Amgen, Dr Cerezo held a number of increasingly senior positions at Pfizer, where he was Senior Director of Global Medical Affairs for the Bococizumab program before becoming Global Medical Team Leader for Eliquis.
Prior to joining the pharmaceutical industry, Dr Cerezo practiced for over 15 years in various units of internal medicine. During his last seven years, he has been a member of a specialized cardiovascular and renal unit, in which he has been a researcher and practitioner, publishing and lecturing in several relevant scientific journals and forums. He has also worked as a professor of clinical pharmacology, semiology and epidemiology at the European University of Madrid.
Cesar obtained his doctorate in medicine and surgery from the Complutense University of Madrid, Spain, in 1998 and completed a residency in family and community medicine in 2002. He obtained his doctorate. in Cardiovascular Diseases from the Autonoma University of Madrid in 2012, where his thesis focused on the chronic suppressing effect of the renin-angiotensin system on urinary albumin excretion in patients with high blood pressure. CÃ©sar also holds a specialist degree in vascular risk prevention from the Complutense University of Madrid.
For more information, please visit www.grifols.com or www.alkahest.com.
Grifols is a global healthcare company founded in Barcelona in 1909, committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostics, Hospital and Bio Supplies – develop, produce and market innovative solutions and services which are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols operates a growing network of donation centers around the world. It transforms the collected plasma into essential medicines to treat chronic, rare and sometimes fatal conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to improve the safety of donation to transfusion. In addition, the company provides tools, information and services that enable hospitals, pharmacies and healthcare professionals to effectively deliver specialized medical care.
Grifols, with nearly 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.
In 2020, Grifols’ economic impact in its main countries of operation was 7.5 billion euros. The company has also generated 140,000 jobs, including indirect and induced.
The company’s Class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Grifols Class B non-voting shares are listed on the Mercado Continuo (MCE: GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS).
Alkahest is a clinical-stage biopharmaceutical company dedicated to the discovery and development of treatments for neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes several therapeutic candidates ranging from selected plasma fractions to targeted protein interventions that aim to slow down the harmful biological processes of aging.
For more information, please visit www.grifols.com or www.alkahest.com.
1 (646) 751-4362
Grifols Media press office
Phone. +34 571 00 02
Facts and figures contained in this report which do not refer to historical data are âfuture projections and assumptionsâ. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated â,â future âand similar expressions, as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, assumptions, expectations and forecasts of the management team at the time of writing, and these are subject to a number of factors which mean that actual results may differ materially. The future results of the Grifols group could be affected by events related to its own activities, such as a disruption in the supply of raw materials for the manufacture of its products, the appearance of competing products on the market, or changes in the market. regulatory framework of the markets in which it operates, among others. At the time of writing this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, SA accepts no obligation to publish, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing of this report, unless expressly required by applicable law. . This document does not constitute an offer or an invitation to buy or subscribe for shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving the recast text of the Securities Market Law movable; Royal Decree Law 5/2005, of March 11 and / or Royal Decree 1310/2005, of November 4, and any regulations developing this legislation. In addition, this document does not constitute an offer to buy, sell or exchange, nor a request for an offer to buy, sell or exchange securities, nor a request for a vote or approval in any other jurisdiction. The information contained in this document has not been verified or reviewed by the external auditors of the Grifols group.